Recently, we developed a risk score for antiphospholipid syndrome (APS) (Global APS Score or GAPSS). This score derived from the combination of independent risk factors for thrombosis and pregnancy loss, taking into account the antiphospholipid antibodies (aPL) profile (criteria and non-criteria aPL), the conventional cardiovascular risk factors, and the autoimmune antibodies profile. We demonstrate that risk profile in APS can be successfully assessed, suggesting that GAPSS can be a potential quantitative marker of APS-related clinical manifestations.
SciasciaSCuadradoMJKarimMY. Management of infection in systemic lupus erythematosus. Best Pract Res Clin Rheumatol2013; 27: 377–389.
4.
OtomoKAtsumiTAmengualO. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum2012; 64: 504–512.
5.
SciasciaSSannaGMurruVRoccatelloDKhamashtaMABertolacciniML. GAPSS: The Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford)2013; 52: 1397–1403.
6.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Thromb Haemost2006; 4: 295–306.
7.
BertolacciniMLAmengualOAtsumiT. ‘Non-criteria’ aPL tests: Report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus2011; 20: 191–205.
8.
SciasciaSSannaGMurruVRoccatelloDKhamashtaMABertolacciniML. Prospective validation of the Global Antiphospholipid Syndrome Score (GAPSS). Arthritis Rheum2013; 65: S3–S3.
9.
Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. The Global Antiphospholipid Syndrome Score (GAPSS) in primary APS. Rheumatology (Oxford) 2014; in press.
